Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H25N7O6.2C6H13NO5 |
Molecular Weight | 817.798 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO.N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO.CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC3=C1C(=O)NC(N)=N3
InChI
InChIKey=FZDRYCKUVGVDSO-KWWXADPNSA-N
InChI=1S/C20H25N7O6.2C6H13NO5/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29;2*7-3(1-8)5(11)6(12)4(10)2-9/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31);2*1,3-6,9-12H,2,7H2/t12-,13-;2*3-,4+,5+,6+/m000/s1
Molecular Formula | C6H13NO5 |
Molecular Weight | 179.1711 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C20H25N7O6 |
Molecular Weight | 459.4558 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Levomefolate glucosamine is prodrug of Levomefolic acid. Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma. It is transported across the membranes including the blood-brain barrier into various tissues where it plays an essential role in the DNA synthesis, cysteine cycle and regulation of homocysteine, where it methylates homocysteine and forms methionine and tetrahydrofolate (THF). Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound. It is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement. Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:04:20 GMT 2025
by
admin
on
Mon Mar 31 23:04:20 GMT 2025
|
Record UNII |
Q65PL71Q1A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Q65PL71Q1A
Created by
admin on Mon Mar 31 23:04:20 GMT 2025 , Edited by admin on Mon Mar 31 23:04:20 GMT 2025
|
PRIMARY | |||
|
100000174527
Created by
admin on Mon Mar 31 23:04:20 GMT 2025 , Edited by admin on Mon Mar 31 23:04:20 GMT 2025
|
PRIMARY | |||
|
DBSALT001567
Created by
admin on Mon Mar 31 23:04:20 GMT 2025 , Edited by admin on Mon Mar 31 23:04:20 GMT 2025
|
PRIMARY | |||
|
1592256
Created by
admin on Mon Mar 31 23:04:20 GMT 2025 , Edited by admin on Mon Mar 31 23:04:20 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID101019760
Created by
admin on Mon Mar 31 23:04:20 GMT 2025 , Edited by admin on Mon Mar 31 23:04:20 GMT 2025
|
PRIMARY | |||
|
Q65PL71Q1A
Created by
admin on Mon Mar 31 23:04:20 GMT 2025 , Edited by admin on Mon Mar 31 23:04:20 GMT 2025
|
PRIMARY | |||
|
135565261
Created by
admin on Mon Mar 31 23:04:20 GMT 2025 , Edited by admin on Mon Mar 31 23:04:20 GMT 2025
|
PRIMARY | |||
|
1181972-37-1
Created by
admin on Mon Mar 31 23:04:20 GMT 2025 , Edited by admin on Mon Mar 31 23:04:20 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY | |||
|
ACTIVE MOIETY |